<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132234</url>
  </required_header>
  <id_info>
    <org_study_id>UJ-KChWiMWsi-Reu</org_study_id>
    <nct_id>NCT02132234</nct_id>
  </id_info>
  <brief_title>Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis</brief_title>
  <official_title>Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jagiellonian University</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the influence of anti tumor necrosis factor-alpha&#xD;
      (TNF-α) treatment on blood pressure, endothelial function and immune cell phenotype in&#xD;
      patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in blood pressure</measure>
    <time_frame>prior to receiving anti-TNF-α treatment, 12 weeks</time_frame>
    <description>Ambulatory Blood Pressure Monitoring (ABPM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in endothelial function</measure>
    <time_frame>prior to receiving anti-TNF-α treatment, 12 weeks</time_frame>
    <description>Flow Mediated Dilatation / Endo Pat</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in immune cell subset populations from baseline</measure>
    <time_frame>prior to receiving anti-TNF-α treatment, 12 weeks</time_frame>
    <description>determination of subsets, activation markers, intracellular cytokine production</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Biological treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high disease activity receiving biological treatment according to rheumatologic indication:&#xD;
etanercept 50 mg s.c. every week&#xD;
adalimumab 40 mg s.c. every 2 weeks&#xD;
certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks&#xD;
infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with high disease activity receiving other than biological treatment and receiving placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>biological treatment according to rheumatologic indication</description>
    <arm_group_label>Biological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>biological treatment according to rheumatologic indication</description>
    <arm_group_label>Biological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab</intervention_name>
    <description>biological treatment according to rheumatologic indication</description>
    <arm_group_label>Biological treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>biological treatment according to rheumatologic indication</description>
    <arm_group_label>Biological treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For patients suffering from rheumatoid arthritis:&#xD;
&#xD;
          -  rheumatoid arthritis diagnosed based on The American Rheumatism Association Criteria&#xD;
             from 1987&#xD;
&#xD;
          -  ineffective treatment with 2 disease-modifying antirheumatic drugs (DMARDs) for 6&#xD;
             months each, including treatment with maximal doses of methotrexate for at least 3&#xD;
             months (or intolerance to treatment)&#xD;
&#xD;
          -  high disease activity - Disease Activity Score 28 (DAS 28) &gt; 5,1 measured twice, with&#xD;
             a 1-month interval&#xD;
&#xD;
          -  for patients with mainly lower limbs affected with DAS 28 &gt; 3,7&#xD;
&#xD;
        For patients suffering from Ankylosing Spondylitis:&#xD;
&#xD;
          -  Ankylosing Spondylitis diagnosed based on Modified New York Criteria&#xD;
&#xD;
          -  ineffective treatment with 2 non-steroidal anti-inflammatory drugs (administered&#xD;
             separately) in maximal recommended or maximal tolerated dose for 3 months&#xD;
&#xD;
          -  high disease activity -Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &gt; 4&#xD;
             measured twice, with a 12-week interval&#xD;
&#xD;
          -  spinal pain &gt; 4cm on 10cm Visual Analogue Scale (VAS) measured twice, with a 12-week&#xD;
             interval&#xD;
&#xD;
          -  general disease activity assessment &gt; 5 (0-10 scale) performed after the 2nd VAS and&#xD;
             BASDAI assessment&#xD;
&#xD;
        For patients suffering from Psoriatic Arthritis:&#xD;
&#xD;
        - Psoriatic arthritis diagnosed based on the Bennett or Classification Criteria for&#xD;
        Psoriatic Arthritis (CASPAR Criteria)&#xD;
&#xD;
        If peripheral joints are affected:&#xD;
&#xD;
        active disease assessed twice, with a 4-week interval on stable treatment, after 2 DMARDs&#xD;
        treatment for at least 4 months&#xD;
&#xD;
        Criteria of active disease (all have to be met):&#xD;
&#xD;
          -  At least 5 out of 66 joints swollen - assessed twice, with a 4-week interval&#xD;
&#xD;
          -  At least 5 out of 68 joints tender - assessed twice, with a 4-week interval&#xD;
&#xD;
          -  general disease activity assessment of 4 or 5 in the Likert scale (0- 5 scale)&#xD;
             performed by patient&#xD;
&#xD;
          -  general disease activity assessment of 4 or 5 in the Likert scale (0- 5 scale)&#xD;
             performed by physician&#xD;
&#xD;
          -  general disease activity assessment &gt; 5 (0-10 scale) performed after 2nd assessment of&#xD;
             number of tender and swollen joints&#xD;
&#xD;
        If axial joints are affected:&#xD;
&#xD;
          -  Sacroiliac joints affected according to the New York Criteria of Ankylosing&#xD;
             Spondylitis&#xD;
&#xD;
          -  Active and severe disease assessed twice, with a 12-week interval, stable treatment,&#xD;
             ineffective treatment with 2 nonsteroidal anti-inflammatory drugs (administered&#xD;
             separately) in maximal recommended or maximal tolerated dose for 3 months each&#xD;
&#xD;
        Criteria of active disease (all must be present):&#xD;
&#xD;
          -  BASDAI &gt; 4 measured twice, with a 12-week interval&#xD;
&#xD;
          -  spinal pain &gt; 4cm on 10 cm in the VAS measured twice, with a 12-week interval&#xD;
&#xD;
          -  general disease activity assessment &gt; 5 (0-10 scale) Patients can take steroid in&#xD;
             stable dose within one month - maximal dose 10mg/day of prednisone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-consenting patient&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast-feeding&#xD;
&#xD;
          -  allergy for the drug or any component&#xD;
&#xD;
          -  cardiac insufficiency (NYHA III or IV)&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  infection within the last 3 months: hepatitis, pneumonia, pyelonephritis&#xD;
&#xD;
          -  opportunistic infection within the last 2 months: active infection of cytomegalovirus,&#xD;
             Pneumocystis carinii&#xD;
&#xD;
          -  joint infection within the last 12 months&#xD;
&#xD;
          -  endoprosthesis infection within the last 12 months or any time if the joint was not&#xD;
             replaced&#xD;
&#xD;
          -  exacerbation of lung-, kidney-, liver- or heart insufficiency during treatment&#xD;
&#xD;
          -  demyelinating disease or its symptoms&#xD;
&#xD;
          -  pancytopenia or aplastic anemia&#xD;
&#xD;
          -  pre-cancer stage&#xD;
&#xD;
          -  neoplasm within the last 5 years including solid tumors and neoplasm of haematopoietic&#xD;
             or lymphatic system with risk of recurrence or progression&#xD;
&#xD;
          -  active alcoholic disease&#xD;
&#xD;
          -  chronic liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Guzik, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bogdan Batko, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Rheumatology, J. Dietl Hospital, Krakow, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Katedra Chorób Wewnętrznych i Medycyny Wsi, Uniwersytet Jagielloński</name>
      <address>
        <city>Krakow, Skarbowa 4</city>
        <zip>31-121</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogdan Batko, MD, PhD</last_name>
      <phone>48126876261</phone>
    </contact>
    <contact_backup>
      <last_name>Agata Schramm, MD</last_name>
      <phone>48126876210</phone>
    </contact_backup>
    <investigator>
      <last_name>Tomasz Guzik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdan Batko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agata Schramm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <last_update_submitted>May 5, 2014</last_update_submitted>
  <last_update_submitted_qc>May 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Tomasz Guzik</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

